Skip to main content
Premium Trial:

Request an Annual Quote

Andy Arno

OncoCyte has appointed Andy Arno to its board of directors. Currently vice chairman of "The Special Equities Group" at Chardan Capital Markets, Arno has more than 30 years of capital markets experience working with emerging growth firms. His past experience includes being managing director of investment bank Emerging Growth Equities, and vice president of Sabr, as well as president of LOMUSA.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.